Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00745
|
|||||
| Drug Name |
Linagliptin
|
|||||
| Synonyms |
(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione; BI 1356; BI-1356; BI-1356-BS; Ondero; Ondero (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Type 2 diabetes [ICD11: 5A11] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C25H28N8O2
|
|||||
| Canonical SMILES |
CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
|
|||||
| InChI |
InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
|
|||||
| InChIKey |
LTXREWYXXSTFRX-QGZVFWFLSA-N
|
|||||
| CAS Number |
CAS 668270-12-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 472.5 | Topological Polar Surface Area | 114 | ||
| Heavy Atom Count | 35 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
1.9
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:68610
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Linagliptin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.